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Robust platforms for determining differentially expressed proteins in biomarker and discovery studies using human plasma are
of great interest. While increased depth in proteome coverage is desirable, it is associated with costs of experimental time due
to necessary sample fractionation. We evaluated a robust quantitative proteomics workflow for its ability (1) to provide increased
depth in plasma proteome coverage and (2) to give statistical insight useful for establishing differentially expressed plasma proteins.
The workflow involves dual-stage immunodepletion on a multiple affinity removal system (MARS) column, iTRAQ tagging,
offline strong-cation exchange chromatography, and liquid chromatography tandemmass spectrometry (LC-MS/MS). Independent
workflow experiments were performed in triplicate on four plasma samples tagged with iTRAQ 4-plex reagents. After stringent
criteria were applied to database searched results, 689 proteins with at least two spectral counts (SC) were identified. Depth in
proteome coverage was assessed by comparison to the 2010 Human Plasma Proteome Reference Database in which our studies
reveal 399 additional proteins which have not been previously reported. Additionally, we report on the technical variation of this
quantitative workflow which ranges from ±11 to 30%.
1. Introduction
Discovery studies using plasma proteomics present chal-
lenges due to the technical difficulties associated with mea-
suring the large dynamic range (∼10–12 orders of magnitude)
of proteins that exist in this medium [1]. Low-abundance
proteins, which are of interest for biomarker applications,
are often only accessible with involved proteomics workflows
that utilize multiple sample fractionation steps. While the
development of specific clinical immunoassays would resolve
this approach, much work needs to be done in this area.
Enrichment strategies for low-abundance plasma proteins
rely on immunodepletion of high-abundance proteins [2–5],
and, more recently, tandem depletion strategies have been
employed [6–9]. For example, proteins present in as little
as 1–1.6 𝜇g⋅mL−1 concentrations are detectable using tandem
removal of abundant proteins with human serum albumin
and Human 14 (Hu 14) multiple affinity removal system
(MARS) columns [9]. A two-stage depletion setup that
involves serial IgY and Supermix columns has also been
effective in increasing the number of detectable low abun-
dance proteins without affecting quantitative accuracy and
precision using isobaric tags for relative and absolute quan-
tification (iTRAQ) [6].
Recently, an updated reference database of human plasma
proteins was released from the Human Proteome Organiza-
tion which includes 1929 nonredundant protein sequences
[10]. This list includes proteins that were identified amongst
∼30 laboratories that utilized various enrichment and deple-
tion strategies, shotgun proteomics techniques, and liquid,
chromatography tandem mass spectrometry (LC-MS/MS)
platforms. Herein, we report additions to the released ref-
erence database based on results obtained from the analysis
of plasma samples in our laboratory analyzed by a dual
depletion shotgun proteomics technique.
Quantitative proteomics analyses of plasma are useful for
identifying clinically relevant biomarkers [4] or in under-
standing diseasemechanisms such asAlzheimer’s disease [11].
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The inherent biological variability across human patients can
require a large number of samples in order to determine
differentially expressed proteins that are statistically relevant.
Depending on factors such as instrumental platform and
available instrument time, multiplexing strategies are attrac-
tive. The commercial iTRAQ reagent allows up to eight sam-
ples to be multiplexed and has been effective in identifying
biomarkers or differentially expressed proteins in diseases
[12–14]. Limitations to this quantitative approach can include
cost of reagent kits and issues with underestimation of ratios
[15].
Nonetheless, iTRAQ can provide reliable quantitative
information depending on the statistical rigor required for
denoting proteins as differentially expressed [6, 16–19]. Sev-
eral reports have stressed the importance of biological and
technical replication in iTRAQ-based quantitative studies
[13, 16, 19, 20].These reports, however, do not converge on the
same finite set of criteria for determining statistically relevant
differentially expressed proteins. For example, Song et al.
suggest that at least 20 or 8 biological samples are required
in order to use fold change cutoff values of 1.5 and 2.0,
respectively [19]. Chee et al. employ a ±30% or ±50% cutoff
for technical and biological replicates, respectively [16]. Most
recently, a fold change >2 was deemed appropriate when at
least six biological sample replicates are employed in order to
have sufficient statistical power [21]. That the criteria should
even converge has also been questioned as it has been pro-
posed that fold change cutoff values are dependent on many
factors: replications, number of observed peptides, protein
class (e.g., high or low abundance), and so forth; specific
values should be defined based on experimental goals and
design [22].
Herein, we evaluate a robust tandem depletion quantita-
tive proteomics workflow for its ability to provide additional
insight to the human plasma proteome and to provide suit-
able criteria for the statistically relevant determination of
differentially expressed proteins in human plasma.
2. Materials and Methods
2.1. Plasma Samples. Four plasma samples were obtained
from patients enrolled in the Genetic and Inflammatory
Markers of Sepsis (GenIMS) study [23]. These patients were
initially diagnosed with community-acquired pneumonia
upon admittance to the emergency department, and samples
were collected; however, further diagnoses revealed improper
initial assessment. Thus these samples come from otherwise
healthy volunteers. Approval for the participation of human
subjects was obtained by the institutional review board of the
University of Pittsburgh and other participating sites.
2.2. Tandem MARS Immunodepletion (TMD). The Hu 6
MARS column depletes serum albumin, IgG, 𝛼1-antitrypsin,
IgA, transferrin, and haptoglobin proteins. An injection
amount of 60 𝜇L of crude plasma was applied to the MARS
column (Agilent; Santa Clara, CA, USA), and after the initial
depletion, flow-through fractions were concentrated with
a 5K molecular weight cutoff concentrator (Agilent; Santa
Clara, CA, USA) at 4695 g for 1.5 hours. Samples (hereafter
referred to as MD) were then stored at −80∘C or reinjected
onto the MARS column for tandem MARS depletion. The
second flow-through fractions (hereafter referred to as TMD)
were concentrated, and protein concentrations were mea-
sured using the BCA protein assay.
2.3. Protein Digestion and iTRAQ Labeling. In order to nor-
malize experimental conditions, similar amounts of protein
(i.e., 100 𝜇g) as determined from a BCA assay were employed.
Protein amounts as opposed to sample volumes were used
since the concentrations of proteins in the flow-through
fraction may vary across samples after TMD. A total of
100 𝜇g of protein was denatured with an extraction buffer
(0.2M Tris, 8M urea, 10mM CaCl
2
, pH 8.0), reduced with
1 : 40 molar excess of dithiothreitol for 2 h at 37∘C, and then
alkylated with 1 : 80 molar excess of iodoacetamide for 2 h
on ice in the dark. The alkylation reaction was quenched by
adding 1 : 40 molar excess of cysteine, and the mixture was
incubated at room temperature for 30min. Molar excesses
for each reagent was calculated based on an estimation of
the total moles of protein in each sample (i.e., average MW
of ∼66 kDa). Tris buffer (0.2M Tris, 10mM CaCl
2
, pH 8.0)
was added to dilute the urea concentration to 2M. Each
sample was incubated with bovine TPCK-heated trypsin at
50 : 1 substrate: enzyme mass ratio for 24 h at 37∘C. Digested
samples were desalted with an HLB cartridge (Waters; Mil-
ford, MA, USA) and dried by centrifugal evaporation. Each
sample was labeled with an iTRAQ reagent following the
manufacturer’s protocol (Applied Biosystems; Foster City,
CA, USA) with slight modifications. Briefly, each iTRAQ
reagent was solubilized with 70 𝜇L ethanol and transferred to
peptide mixtures. After 1.5 h of incubation, the reaction was
quenched by adding 50 𝜇L of water. Labeled samples were
mixed in 1 : 1 : 1 : 1 ratios for iTRAQ reagents that generate
reporter ionsm/z 114 : 115 : 116 : 117, respectively.
2.4. Offline SCX Fractionation. For strong-cation exchange
(SCX) liquid chromatography the separation was carried out
on a polysulfoethyl 100mm × 2.1mm, 5 𝜇m, 200 A˚ column
(TheNest Group Inc.; Southborough,MA, USA) with buffers
as follows. Mobile phase A was 5mMmonopotassium phos-
phate (25% v/v acetonitrile, pH 3.0), and mobile phase B
was 5mM phosphate and 350mM potassium chloride (25%
v/v acetonitrile, pH 3.0). Dried iTRAQ-labeled samples were
resuspended in 300 𝜇L of mobile phase A and injected onto
the SCX column. The gradient for SCX was 0–3min, 0% B;
3–45min, 0–75% B; 45–50min, 75–100% B; 50–55min, 100%
mobile phase B; 55–56min, 100–0% B; and 56–106min, 0%
B. Thirteen SCX fractions were collected, and each fraction
was desalted with an HLB cartridge.
2.5. LC-MS/MS. Online desalting and reversed phase chro-
matography was performed with a Nano 2D-LC system
equipped with an autosampler (Eksigent; Dublin, CA, USA).
Mobile phase A and B for these analyses were 3% (v/v)
acetonitrile with 0.1% formic acid and 100% (v/v) ace-
tonitrile with 0.1% formic acid, respectively. SCX fractions
were solubilized in 50𝜇L of H
2
O with 0.1% formic acid
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and filtered with a 0.45 𝜇m filter (Thermo Fisher Scientific;
Waltham,MA,USA). For each run, 5 𝜇Lof samplewas loaded
into a trapping column (100 𝜇m i.d. × 2 cm), which was
packed in-house with C
18
200 A˚ stationary phase material
(MichromBioresource Inc.; Auburn, CA,USA) at 3𝜇L⋅min−1
in 3% mobile phase B for 3min. After desalting, the sample
was loaded into the analytical column (75𝜇m i.d.× 13.2 cm),
which was packed in-house with C
18
100 A˚ stationary
phase material (Michrom Bioresource Inc.). The gradient
was as follows: 0–5min, 10% mobile phase B; 5–75min, 10–
30% B; 75–95min, 30–60% B; 95–100min, 60–90% B; 100–
105min, 90–10% B; and 110–120min, 10% B. The LC eluent
was analyzed with positive-ion nanoflow electrospray using
a LTQ-Orbitrap Velos mass spectrometer (Thermo-Fisher
Scientific, Waltham, MA, USA). Data-dependent acquisition
parameters were as follows: the MS survey scan in the
Orbitrap was 60,000 resolution over 300–1800m/z; CID was
performed on the ion trap with normalized collision energy
35%; HCD was recorded in the Orbitrap with normalized
collision energy 45% and 7,500 resolution; the top six most
intense ions in the parentMS scanwere selected and activated
using CID and HCD [24]; dynamic exclusion was enabled
with a repeat count of 2 for a duration of 60 sec; a minimum
of 5000 ion counts were necessary for fragmentation events.
Each fraction was subject to triplicate LC-MS/MS.
2.6. Database Searching. RAW files were analyzed with Pro-
teomeDiscoverer 1.2 software (Thermo). Both CID andHCD
spectra were used to obtain sequence information against
the UniProt human database (04/25/2010, 20295 sequences).
Sequest search parameters were as follows: enzyme specificity
was trypsin with two maximum miscleavages; precursor
mass tolerance was 10 ppm; fragment mass tolerance was
0.8Da; N-terminus and lysine modification with iTRAQ
(144.102Da) and cysteine carbamidomethylation (57.021Da)
were set as fixed modifications; tyrosine modification with
iTRAQ was set as a dynamic modification. Decoy database
searching was employed to generate medium (𝑃 < 0.05) and
high (𝑃 < 0.01) confidence peptide lists. All peptides with
medium and high confidence were pooled into a single data
file and used for final protein identification and quantitation.
Proteins with at least two spectral counts in a workflow
replicate were included for identification. Only proteins with
at least two spectral counts in a technical replicate were
considered for quantitative and statistical analysis. One-
way ANOVA analysis (𝑃 < 0.05) was performed for pro-
teins quantified in at least two workflow replicates utilizing
Microsoft Excel.
2.7. Protein Quantification and Statistical Analysis. Peptide
ratios (e.g., 115/114, 116/114, and 117/114) were calculated based
on the peak intensity of each reporter ion. The protein ratios
were the median ratio of the corresponding peptide ratios.
Coefficients of variation (CV) values were calculated for
ratios of proteins quantified in at least two workflow repli-
cates. The mean CV value across workflow replicates was
calculated and used as the total biological variation, 𝑆
𝑏
. The
technical variation, 𝑆
𝑡
, was calculated for proteins quantified
in at least two LC-MS/MS analyses within an individual
workflow. The relation between the fold change (𝐹), random
variation (𝑆), biological replicates per group (𝑛), and tech-
nical replicates (𝑚) has been previously reported [25] and
is expressed by the formula
𝑛 =
2(𝑍 + 𝑇)
2
𝑆
2
(𝐹 − 1)
2
,
𝑆 = (
𝑆
2
𝑏
+ 𝑆
2
𝑡
𝑚
)
1/2
.
(1)
The quantities 𝑍 and 𝑇 depend on the power of the test and
the significance level, respectively. The power and signifi-
cance levels were set as 0.8 and 0.05, respectively, such that
the formula approximates to
𝑛 =
20𝑆
2
(𝐹 − 1)
2
,
𝐹 =
4.47𝑆
𝑛
1/2
+ 1.
(2)
One-wayANOVAanalysis (𝑃 < 0.05) was performed for pro-
teins quantified in at least two workflow replicates utilizing
Microsoft Excel.
3. Results and Discussion
A robust quantitative shotgun proteomics workflow
(Figure 1(a)) was assessed for its ability to identify new
human plasma proteins and to guide future experimental
designs. The workflow uses tandem MARS depletion
(TMD), iTRAQ four-plex reagents, SCX fractionation, and
nanoflow LC-MS/MS on a LTQ-Orbitrap Velos MS. The
entire workflow was repeated three times using new aliquots
of four plasma samples that were subject to TMD using
a Hu 6 MARS column. The time it takes to complete a
single workflow replicate is ∼7 days with a majority of the
costs being attributed to the MARS column (∼200 analyses
per column) and the iTRAQ reagents (5 analyses per kit).
Immunodepletion of samples is very reproducible for
single-stage MARS depletion (MD, Figure 1(b)) and TMD
(Figure 1(c)). It is apparent from the chromatograms
(Figures 1(b) and 1(c)) that high abundance proteins (i.e.,
𝑡
𝑟
∼ 12.5min) are substantially depleted after the TMD step.
The average % depletion of the six high abundance proteins
is 88% and 92% for MD and TMD, respectively, (see Sup-
plementary Table S1 of the Supplementary Material available
online at http://dx.doi.org/10.1155/2013/654356) and is similar
to that obtained using other tandem depletion strategies
[6, 8, 9]. It should be noted that albumin was still detectable
after TMD (Supplementary Table S2); however other
abundant proteins (i.e., 𝛼-1-antitrypsin, IgG, IgA, transferrin,
and haptoglobin) did not have any observed peptide hits.The
most abundant protein detected based on spectral counts was
complement C3 which had an average total spectral count
(SC) of >4000 across the workflow replicates (Supplementary
Table S2). The use of a single column to perform dual
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Figure 1: (a)The iTRAQ-based quantitative platform used for plasma proteome analyses in which the flow-through fractions from four crude
plasma samples (A–D) are modified with iTRAQ 4-plex reagents, pooled into a single mixture, and separated with offline SCX-LC-MS/MS.
Example chromatograms (𝜆
280 nm) from three independent injections of plasma sample C upon (b) MD and (c) TMD are shown.
immunodepletion minimizes the expenses associated with
the use of multiple MARS or other depletion columns.
TMD samples were used for further iTRAQ tagging
reactions and analyzed with SCX LC-MS/MS (Figure 1(a)). A
total of 689 unique proteins were identified from the com-
bined results of the three independent workflow experiments
(Supplementary Table S2) and are slightly larger than the
number of proteins observed in other reports [5, 9, 19, 26, 27].
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Figure 2: (a) Venn diagram for proteins identified in the human
plasma proteome project (HPPP) and the TMDworkflow presented
herein. (b) Venn diagram for proteins identified in three workflow
replicate (WR) experiments.
The proteins identified in this study were compared to the
recently released 2011 HUPO plasma protein database to
assess the depth of proteome coverage. Based on comparisons
of identified proteins to the 1929 nonredundant sequences
reported in the Human Proteome Organization Database
[10], 399 novel proteins with ≥2 SC are uniquely observed
in these studies (Figure 2(a)). Although the incorporation
of a dual depletion step and SCX fractionation increases
experimental sample preparation time, our results support
the necessity of these (or similar) steps for identification of
commonly detected and novel plasma proteins. Due to dif-
ferent experimental designs, LC-MS/MS data acquisition
settings, and searching engines, the number of identified
proteins may vary a lot across different labs. It is also possible
that a portion of the identifications are a result of profiles
specific to the patient samples employed. All of the proteins
identified are provided in Supplementary Table S2. A total
of 207 proteins were observed in all three of the workflow
experiments, and more than half of the total proteins were
observed in a single workflow replicate (Figure 2(b)). With
more stringent criteria (i.e., not less than 2 unique peptides
for protein identification), 229 proteins were identified across
three workflow replicates, and 40 new proteins were identi-
fied in these studies in comparison to the HUPO database.
The datasets collected from this TMD strategy were used
to examine the variation in the entire workflow. iTRAQ
reporter ion (i.e., m/z 115, 116, and 117) ratios were calculated
with respect to m/z 114 for each protein. Proteins quantified
by at least 2 spectral counts were used in the assessment
of variation. Of the 207 proteins identified in all three
workflow replicates, 139 proteins (with at least 2 spectral
counts) were quantified in the ProteomeDiscoverer Analysis.
These proteins were used to initially assess the variance in
reporter ion ratios across the workflow replicates (of which
each includes three technical replicates) by employing well-
established statistical approaches [25, 28–31]. We refer to a
technical replicate as the cumulative results obtained across
individual LC-MS/MS analyses of the 13 SCX fractions.
Thus within a single workflow experiment three technical
replicates were measured.Theworkflow replicate assesses the
variation beginning with the start of the plasma sample prep-
aration.
Figure 3(a) plots the distribution of CV values for pro-
teins as a function of reporter ion ratios (e.g., 115/114, 116/114,
and 117/114). The distribution of SD values for proteins as
a function of log
2
transformed ratios are provided in Sup-
plementary Figure 1. Within a single workflow replicate, the
average reporter ion ratio across technical replicates was
calculated for individual proteins. The corresponding mean
(andmedian) CV values for ratios 115/114, 116/114, and 117/114
across all proteins quantified in the three workflow replicates
was ±0.16 (0.13), 0.13 (0.11), and 0.11 (0.09), respectively.
Seventy-five percent of proteins had a CV <0.16, and 90% of
proteins had a CV <0.21 when reporter ion 114 was used as
the reference channel. Because the reporter ion channel used
as the reference can have some effect on quantitation [19],
the mean (and median) CV values were also calculated for
different reference channels (Supplementary Table S3).When
reporter ions m/z 115, 116, and 117 were used as the reference
channel, 90% of proteins had a CV value <0.28, 0.21, and
0.24, respectively. This range of CV values that results from
selection of different reference channels reflects the variation
inherent in the four plasma samples as well as any variation
that arises during LC-MS/MS analysis.
Incorporation of multiple workflow or technical repli-
cates does not imply that proteins will be observed in all
experiments (Figure 2(a)); therefore CV values were also
calculated for the 71 proteins that were only quantified in
any two of the three workflow replicates. When reporter ion
m/z 114 was used as the reference channel, the mean (and
median) CV was ±0.30 (0.23), 0.20 (0.15), and 0.18 (0.15)
for ratios 115/114, 116/114, and 117/114, respectively (Supple-
mentary Table S3). The higher CV observed for this set of
proteins agreeswith the notion that less replication (workflow
and technical) could lead to higher variation in reporter ion
ratios [20, 28] as well as biases that arise in low abundance
proteins due to lower numbers of detected spectral counts
and higher variability due to lower intensity signals [22].
Higher variability in reporter ion ratios correlated with
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Figure 3: (a) The distribution of CV values for 𝐼
115
/𝐼
114
(grey rectangular), 𝐼
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for proteins quantified in each of the three independent experiments (𝑁 = 139 proteins). The cumulative frequency of proteins with specific
CV values for 𝐼
115
/𝐼
114
(dashed square), 𝐼
116
/𝐼
114
(dashed triangle), and 𝐼
117
/𝐼
114
(dashed circle) are shown. CV values are given as fractional
values. The total peak intensity is represented by I. (b) Plot of the mean CV values for reporter ion ratios relative to reference channel 114 as a
function of the number of spectral counts identified for each protein. Only proteins identified in all three workflow replicates are represented
in this plot. (c) Power analysis for iTRAQ-based quantitative platformwhereby fold change values are plotted for a given number of biological
replicates as a function of the number of technical replicates (i.e., 𝑚 = 1 to 4). The power and significance level values were set to 80% and
0.05, respectively.
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proteins that were identified with lower numbers of spectral
counts (Figure 3(b)).
In order to estimate the overall variance of this workflow,
CVvalueswere obtained for proteins quantified in at least two
of the workflow replicates (𝑁 = 210). Themean CV was 0.21,
0.15, and 0.13 for ratios 115/114, 116/114, and 117/114, respec-
tively, and similar values were obtained for other reference
channels (Supplementary Table S3). Taking the CV values of
reference channel 114 into consideration, the overall variation
in the entire plasma workflow is ∼0.16. Herein, the technical
variation was assessed by considering proteins observed in
multiple LC-MS/MS analyses for individual workflow repli-
cates. The technical variation is ∼0.10 for proteins quantified
in at least two replicates (Supplementary Table S4). In order
to determine proteins that were quantified similarly across
workflow replicates, one-way ANOVA analysis (𝑃 < 0.05)
[31] was carried out. Based on these results, ∼70% of the
210 quantified proteins have similar ratios across workflow
replicates (data not shown).
Power analysis was also performed in order to assess the
fold-change criterion that should be applied based on a given
number of biological replicates (Figure 3(c)). We note that
our experimental approach (i.e., repeating theworkflowusing
new aliquots of the same plasma samples) does not represent
a true biological replicate.However, this analysis still provides
statistical insight to the power of biological replication in
future experimental designs. The total biological variance
(𝑆
𝑏
), technical variance (𝑆
𝑡
), power, and significance level
applied were 0.16, 0.10, 80%, and 0.05, respectively. As indi-
cated in Figure 3(c), if ten biological replicates per group
are used then a fold-change cutoff of 1.3 can be applied,
and only two replicates are required to use the commonly
applied 2.0 fold-change cutoff. Technical replicates do not
appear to have a significant effect on the fold-change criterion
whenmultiple biological replicates will be used (Figure 3(c)).
These data provide additional evidence to support the notion
that biological replication (i.e., in these studies workflow
replication) is one of the most important factors that should
be considered in the experimental design [16, 21, 25].
This paper has presented a robust quantitative plasma
proteomics workflow that involves tandemMARS depletion,
iTRAQ tagging, and SCX-LC-MS/MS analysis. The use of
TMD and SCX fractionation resulted in the identification of
689 proteins with ≥2 SC. Compared to the HUPO database,
∼400 of these proteins were previously unreported. The use
of TMD and SCX fractionation significantly increases the
number of proteins detected. The overall variation in the
presented workflow ranges from ±11 to 30%, and power
analysis indicates that increasing biological replication would
allow a lower fold-change cutoff to be applied to deter-
mine statistically relevant differentially expressed proteins.
Future studies from our laboratory involve the application
of this workflow to specific disease states whereby biological
replicates are also being incorporated into the experimental
design.
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